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Abstract
Background The humerus is the second most common
site of metastatic bone disease involving long bones.
Tumors which have a predilection for dissemination to
bone are those of breast, prostate, thyroid, lung and kid-
ney. The rationale for surgical treatment of these lesions
is to prevent or treat pathological fractures in order to
relieve pain and improve function.
Materials and methods Forty patients who had resection
of the proximal humerus for metastatic bone disease and
reconstruction with a modular prosthesis were retrospec-
tively reviewed.
Results Mean functional outcome was 73.1% (Enneking
score) and better results were achieved when a reverse
prosthesis was implanted. Overall survival was 70% at 1
year, 42.5% at 2 years and 20% at 5 years. Local recur-
rence occurred in 4 patients, each of whom had initially
been treated for a pathological fracture.
Conclusions It is important to follow rational guidelines,
like those of Capanna and Mirels, in order to prevent
pathological fractures and to give the patient a definitive
treatment, as the advances in the management of cancer
prolong the survival of these patients. In this series, sat-
isfactory results were obtained, giving the patients an
acceptable quality of life.
Keywords Bone metastases·Proximal humerus·Modular
prostheses · Pathological fracture
Introduction
Bone metastases are the most common example of bone
malignancies and they largely exceed in number primary
tumors of the skeleton. Bone metastatic disease strongly
affects the survival of patients with cancer: in fact, the
prognosis for patients with metastases ranges from fair to
poor. Patients with lung carcinoma or melanoma that has
metastasized to the skeleton generally have less than a 6-
month median survival; patients with bone metastases
from thyroid and prostate carcinoma present a 45-month
median survival [1].
The humerus is the second most common site of
metastatic disease involving long bones. Humeral lesions
may cause pain, disability and pathological fractures [2].
Untreated pathological fractures involving the extremities
are generally responsible for serious disability. Additio-
nally, the risk of fracture is different in lower and upper
extremities. In fact, the bones of the lower limbs are sub-
ject to weight bearing, which makes 50% destruction a
critical limit for impending fractures [3]. The risk of frac-
tures is certainly lower in the upper limbs. Nevertheless,
important intrinsic and extrinsic characteristics involving
certain districts, such as the proximal humerus, should be
considered as risk factors for spontaneous fractures.
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ysis with low cortical rigidity and the significant rotation-
al and bending forces to which this structure is subject
[4]. In this regard, the definition of impending fracture is
controversial: when destruction is greater than 75% of the
bone’s cross section, the risk of spontaneous fracture is
great [5]. On the other hand, it should also be considered
that, when only one cortex remains, the humerus often
fractures with activities of daily living [5].
There are different treatment options for bone metas-
tases. Chemotherapy and radiation therapy are appropri-
ate treatments for sensitive tumors [6]. Bisphosphonates
are useful in decreasing skeletal complications from
breast and prostate carcinoma and multiple myeloma [7].
Surgery is indicated for intractable pain and for impend-
ing or established pathological fractures [8]. Conventio-
nal surgical strategies for humeral metastases are intrame-
dullary nails, plate fixation and cement augmentation for
reconstruction of large bone defects. Methylmethacrylate
is also an effective adjuvant, both for improving the fixa-
tion with intramedullary nails or plates and for sterilizing
the diaphysis from metastatic microfoci. On the other
hand, when the lesion involves the proximal humerus, the
choice for the optimal surgery is often difficult, especial-
ly when the destruction area involves the epiphysis.
However, advances in chemotherapy and local radia-
tion techniques have led to an improvement in survival of
these patients, and prolonged life expectancy can result in
local progression of disease and failure of conventional
fixation devices [9]. Therefore, a more radical and defin-
itive treatment with prostheses seems to be indicated for
these patients [10]. In the literature, indications for pros-
thetic replacement in patients with bone metastases are
isolated lesions, extensive bone loss, and failed conven-
tional reconstruction with plates or rods [4, 10–12].
Modular prostheses permit an adequate resections and
restoration of acceptable functionality. Moreover, in case
of isolated metastatic lesions, a wide resection and the
implantation of a modular prosthesis may also be indicat-
ed [4, 10, 12–16].
This paper reports our experience with prosthetic
replacement in the treatment of proximal humeral metas-
tases between 1992 and 2006.
Materials and methods
We retrospectively analyzed patients treated in our
department with prostheses between 1992 and 2006 for
proximal humeral metastases. Patients were considered
eligible to receive a prosthesis if they had single metasta-
tic lesions, impending fractures, pathological fractures or
intractable pain not responsive to medical therapy and to
radiation. Exclusion criteria were multiple osteoblastic
lesions, osteolytic lesions with no risk of fracture and
expected survival less than 2 months. 
Indications for surgery in this retrospective series
were compared with the protocol proposed by Capanna
and Campanacci (Table 1) [4]. This protocol provides
rational guidelines for indications for surgery, the type of
operation to be undertaken and the methods of reconstruc-
tion available. Based on these criteria, patients in classes
1, 2 and 3 undergo surgical treatment when possible and
have adjuvant treatment, if indicated. Patients in class 4
are initially referred for conservative treatment.
To evaluate the risk of pathological fractures, we used
the scoring system proposed by Mirels [17], which is
based on site, pain level, nature of the lesion, and size of
the lesion relative to the diameter of the bone (Table 2).
We considered mandatory the surgical treatment of patho-
logical fractures with a score of 9 or higher, while a score
of 8 required further clinical judgment, as described by
others [9].
Functional outcome was assessed using the Musculo-
skeletal Tumor Society (MSTS) scoring system (Enne-
king score) for the evaluation of major skeletal resections
and reconstructions; this score assesses pain, function,
emotional acceptance, hand positioning, manual dexterity
and lifting ability [18]. Oncologic outcome was evaluated
by considering survival, local recurrence and need for
revision surgery or adjuvant therapies.
In all patients, resection was done using a deltopec-
toral approach, which permits a wide view of the antero-
superior area of the proximal humerus. It allows for a
wide resection of the proximal humerus, including the
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Table 1 Summary of the management protocol proposed by Capanna
and Campanacci [4]
Class Description
1 Solitary metastatic lesion
Primary tumor with good prognosis
Interval over 3 years since detection of the primary tumor
2 Pathological fracture at any site
3 Impending fracture in a major long bone
4 Osteoblastic lesions at all sites
Osteolytic or mixed lesions in non-structural bones (fibula,
rib, sternum, clavicle)
Osteololytic lesion with no impending fracture
Table 2 Assessment of the risk of pathological fracture according to
Mirels [17]
Variable 1 point 2 points 3 points
Site Upper limb Lower limb Peritrochanter
Pain Mild Moderate Weight bearing
Lesion Blastic Mixed Lytic
Size related to  <1/3 1/3–2/3 >2/3
bone diameterentire subacromial bursa and the rotator cuff [19]. Me-
tastatic lesions were usually resected by subperiosteal dis-
section, and the rotator cuff tendons were saved, if not
involved by the metastatic disease during surgical explo-
ration or at pre-operative magnetic resonance imaging
(MRI). Modular prostheses were implanted by the same
surgical equipe in our department. The prostheses were
usually cemented in order to sterilize any metastatic
microfoci located in the humeral shaft and to minimize
the risk of pathological periprosthetic fractures.
Results
Between 1992 and 2006, we treated 40 patients (19 wo-
men, 21 men) for proximal humerus metastases. At the
time of surgery, the patients had a mean age of 67 years
(range, 52–75). The predominant primary tumor was
breast carcinoma (13 patients), followed by renal cell car-
cinoma (12 patients), lung carcinoma (6 patients), prosta-
tic carcinoma (5 patients), 2 lesions of unknown primary
tumor, and plasmocytoma and melanoma (1 case each).
Plasmocytoma was included since its biological behavior
and the mechanical implications are similar to those of
metastatic disease [4]. In 39 patients, the humerus alone
was affected and in 1 case both the humerus and the
scapula had metastases. Metastases were detected 6
months to 13 years after the diagnosis of the primary
tumor in 32 patients (80%), while in 8 patients (20%) the
metastasis was the first sign of the malignancy.
In 12 patients (30%) surgery was performed to treat a
pathological fracture (Capanna class 2). In the remaining
28 patients (70%), prosthetic replacement was the pri-
mary treatment of the lesion, and was indicated for an
impending fracture in 18 patients (class 3), for intractable
pain in 5 patients (class 4), and for solitary lesions in 5
patients (class 1). Overall, 10 patients (25%) were admit-
ted to surgery after local radiation therapy had been per-
formed: 5 experienced a pathological fracture. Following
surgery, 10 patients (25%) were treated with local radia-
tion therapy, 15 patients (37.5%) were treated with
chemotherapy and 8 patients (20%) were treated with
immunotherapy.
The patient with both humeral and scapular involve-
ment underwent a modified Tikhoff-Linberg procedure: en
bloc resection of the glenohumeral joint after an extracap-
sular osteotomy of the neck of the scapula, followed by
reconstruction with a modular prosthesis [20] for aesthetic
purposes only. In this case we used an I.O.R. modular pros-
thesis (Officine Ortopediche Rizzoli, Bologna, Italy) (Fig.
1) [21]. In 35 patients, we implanted an RPS endoprosthe-
sis [22] (Lima-Lto, San Daniele del Friuli, Udine, Italy)
(Fig. 2) and, in the last 4 patients treated, we used an SMR
reverse modular prosthesis (Fig. 3) (Lima-Lto). Three
patients were lost to follow-up and the remaining 37 were
followed for a mean of 2.5 years (range, 0.5–12 years).
Functional outcome was evaluated in 36 patients
(90%); it was not evaluated in the patient who received an
I.O.R. modular prosthesis (SMR) for aesthetic reconstruc-
tive purposes only. The overall mean value of the Enne-
king score was 73.1% (95% CI, 69.9% to 76.3%). For
patients with a reverse prosthesis (SMR) and for those
with an anatomical prosthesis (RPS) mean scores were
87.5% (95% CI, 82.7% to 92.3%) and 71.3% (95% CI,
68.2% to 74.4%), respectively.
Oncologic outcome was evaluated in 37 patients and
mean survival was 24.4 months (95% CI, 19 to 29.8
months). Local recurrence-free survival was 23.1 months
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Fig. 1a,b A 65-year-old man with lung carcinoma. a Metastasis
involving both the proximal humerus and the scapula. b He under-
went modified Tikhoff-Linberg procedure and an I.O.R. prosthesis
was implanted. No local recurrence occurred. Survival was 1 year;
death occurred for visceral dissemination
ab
Fig. 2a,b A 72-year-old man with renal cell carcinoma. a Metastasis
in the proximal humerus, initially treated with radiation therapy,
caused a pathological fracture. b Treatment with a modular RPS pros-
thesis. Survival was 1 year; death occurred for visceral dissemination
ab(95% CI, 17.5 to 28.7 months). Overall, 70% of patients
survived for 1 year after surgery, 42.5% survived for 2
years and 20% survived for 5 years or more (Fig. 4). Four
patients presented a local recurrence between 6 and 12
months after surgery: the primary tumor was renal cell
carcinoma in 2 cases, breast carcinoma in 1 case, and lung
carcinoma in 1 case. Interestingly, all of them experienced
previously a pathological fracture. They were then treated
with local radiation therapy. 
We noticed a few complications. Two patients experi-
enced an early superficial wound infection, treated suc-
cessfully with antibiotic therapy. No deep infections were
reported. Superior dislocation of the humeral head oc-
curred in 3 cases, when sparing the rotator cuff was not
possible, and an RPS prosthesis was implanted: revision
surgery was performed by changing the humeral head with
a CTA (Cuff Tear Arthropathy) head (Lima-Lto). Gleno-
sphere loosening and dislocation of the prosthesis occurred
in one patient who underwent adjuvant local radiation ther-
apy: revision surgery was performed by changing the
humeral head with a CTA head (Fig. 3) (Lima-Lto).
Discussion
The aim of surgical treatment of bone metastases is to
prevent or stabilize pathological fractures, relieve pain,
avoid local recurrence and permit a satisfactory function-
ality of the operated limb in order to achieve an accept-
able quality of life. Short-term improvement in pain and
functional status seems particularly desirable for patients
with limited life expectancy [6]. Moreover, operative
treatment for pathological fractures of the humerus is gen-
erally superior to nonoperative methods of fracture man-
agement such as splints or casts [23]. As a matter of fact,
Flemming and Beals demonstrated non-union in 50% of
cases and inadequate pain control in 88% of patients treat-
ed nonoperatively [23].
Pathological fracture always requires an extended
time to heal, and as many as 50% will never heal at all
[24]. Moreover, radiation therapy used to treat tumor
pain can delay fracture healing. Biomechanical features
of the proximal humerus are slightly different from those
of the lower limb, because of the absence of weight bear-
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Fig. 3a-c A 52-year-old man with prostatic
carcinoma. a Pathological fracture of the hu-
merus. b After implantation of an SMR rever-
se prosthesis, local radiation therapy caused
glenosphere loosening and dislocation of the
prosthesis. c Revision surgery involved chan-
ging the humeral head with a CTA head. The
patient is still alive with a follow-up of 4 years ab c
Fig. 4 Kaplan-Meier plots of overall survi-
val and local recurrence-free survival. Lo-
cal recurrences presented between 6 and 12
months after implantation
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61 8ing. Nevertheless, there are important rotational and
bending forces due to the action of the rotator cuff, del-
toid, pectoralis maximum and latissimus dorsi.
Additionally, the metaphysis is largely cancellous with
low cortical rigidity; the absence of strong cortical struc-
tures frequently leads to extracompartmental spreading
of the metastatic lesions. For these reasons, osteosynthe-
sis is no longer recommended for metastases in this site,
while the use of modular endoprostheses permits ade-
quate resection with acceptable oncologic and functional
results [4]. Moreover, especially in tumors with a poor
response to radiotherapy, the incidence of complications
is lower after implantation of an endoprosthesis than
after osteosynthesis [25].
In this series, the I.O.R. modular prosthesis [21] allo-
wed for radical resection, such as the modified Tikhoff-
Linberg procedure [20], but it did not permit articular
reconstruction. The RPS prosthesis permitted to achieve
acceptable functional results while performing radical
resections, when it was possible to spare the rotator cuff
and deltoid. On the other hand, when it was mandatory to
resect the rotator cuff, the functional result was usually
unsatisfactory. Moreover, the aim of sparing soft tissues
could result in an inadequate non-radical treatment. 
The SMR modular system, characterized by high
modularity features, permits personalization of the treat-
ment. When it is possible to spare the rotator cuff, it
allows for the implantation of conventional endoprosthe-
ses; when excision of the rotator cuff, capsule and liga-
ments is mandatory, a reverse prosthesis can be implant-
ed. With a reverse prosthesis, it is possible to achieve
good functional results, even in case of wide resections, if
the deltoid insertion is preserved. In reverse prostheses,
the humerus is converted into a socket and the glenoid to
a ball, providing a stable fulcrum for glenohumeral artic-
ulation [26]. This is achieved through maximization of the
length-tension relationship of the deltoid and remaining
cuff musculature [27]. In case of detachment of the
glenosphere due to bone loosening, SMR system permits
substitution of the head with a CTA head, which has a
larger articular area that allows the head to fit into a sock-
et formed by the glenoid and the acromion. When deltoid
activation raises the arm, the head surface remains in con-
tact with the acromion for a longer time, which increases
the amount that the arm can be raised by this muscle. Also
in this case, preservation of the deltoid insertion is
mandatory for obtaining satisfactory results. Results are
also dependent on the patient’s endurance, strength and
participation in rehabilitation [5]. When adjuvant local
radiation therapy is performed, there is a high risk of
glenosphere loosening as highlighted by one of our cases.
Consequently, we no longer implant reverse prostheses
when radiation therapy is planned.
We believe that the risk of pathological fracture is a
more important requirement for surgery than supposed
life expectancy. In fact, all patients who had a local recur-
rence had previously had a pathological fracture, which
may have favored spreading of the tumor in the soft tis-
sues. Obviously, life expectancy should be longer than
recovery from surgery [6, 28, 29]. In order to preserve the
quality of life of these patients, surgery should be defini-
tive[30] and the use of prostheses allows wide resections
of the lesions. This is also a useful technique when
radiochemotherapy cannot be performed.
This study is limited by the fact that it is a retrospec-
tive analysis of heterogeneous group of patients, without
a control group, a preoperative assessment or a quality-
of-life evaluation. Nevertheless, it offers some interest-
ing information. Our current approach to bone metas-
tases, in view of the results of this study and the litera-
ture, is based on Capanna’s criteria [4]. In this series,
satisfactory functional results were achieved with few
complications. The aim of this treatment is to give these
patients an acceptable quality of life, independently
from life expectancy. 
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